FDA Clears LEROCHOL Autoinjector, Adds CV Risk Claim

FDA cleared a self-administered autoinjector for LEROCHOL (lerodalcibep-liga) on 17 August 2026, less than a year after the PCSK9 inhibitor's initial approval. The clearance arrived paired with a labeling update that ties LEROCHOL's LDL-C-lowering effect to a reduction in cardiovascular risk — a claim that changes how the drug can be marketed, not just how it is delivered.

A device supplement, not a new drug review

LEROCHOL's active substance and dose are unchanged; what FDA reviewed and cleared is the delivery device. The new autoinjector is single-use and pressure-activated, built to deliver the identical 300-mg/1.2-mL subcutaneous dose patients already receive from the prefilled syringe FDA approved in December 2025. For a self-administered chronic therapy, the delivery mechanism is not a footnote — injection-site reactions were the most common adverse event in LEROCHOL's trials, and device human-factors testing is the piece of the file most likely to catch a use error that a drug-only review would miss. FDA's clearance covers that device-specific evidence package, filed as a supplement to the existing approval rather than a new application.

The label picks up a cardiovascular-outcomes claim

The more consequential change sits in the label, not the syringe. FDA authorized new language stating that lowering LDL-C with LEROCHOL — like lowering it with statins or monoclonal-antibody PCSK9 inhibitors such as evolocumab or alirocumab — reduces the risk of major adverse cardiovascular events in adults at increased cardiovascular risk. LEROCHOL's original approval was grounded in LDL-C reduction as a surrogate endpoint; this update extends the label's claim toward the outcome physicians and payers ultimately care about, and it puts LEROCHOL's labeling in the same cardiovascular-risk-reduction category the older injectable PCSK9 antibodies have carried for years.

What supported both changes

• Trial base: the global Phase 3 LIBerate program enrolled more than 2,900 patients across cardiovascular-disease, high-risk, and HeFH populations.
• Efficacy: sustained LDL-C reductions of at least 60% in patients with, or at high or very high risk of, cardiovascular disease, and at least 59% in HeFH patients.
• Safety: injection-site reactions in 12% of LEROCHOL patients versus 5% on placebo (18% versus 3% in HeFH), discontinuations around 1%, and no serious treatment-related events reported in the placebo-controlled trials.
• Stability: LEROCHOL carries extended room-temperature stability of up to three months, a storage profile the autoinjector inherits unchanged from the prefilled syringe.

What comes next

LIB Therapeutics expects the autoinjector to reach the US market by January 2027; the prefilled syringe remains available in the interim. LEROCHOL launched in the European Union in June 2026, with first commercial availability in Germany following a February 2026 European Commission approval, and Everest Medicines holds licensing rights for LIB Therapeutics outside the US. For RA and QA teams tracking combination-product pathways, the sequence here — drug approval first, device supplement and label expansion roughly nine months later — is a template other once-monthly injectables are likely to follow as manufacturers move from launch-ready syringes to autoinjectors aimed at improving adherence.